Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1989 Sep;77(3):319–323.

Effect of the new immunoregulator AS-101 on in vitro functions of mononuclear cells from patients with systemic lupus erythematosus.

J Alcocer-Varela 1, D Alarcon-Segovia 1, B Sredni 1, M Albeck 1
PMCID: PMC1542044  PMID: 2530012

Abstract

We studied the in vitro production of interleukin-2 (IL-2), the expression of IL-2 receptors, the absorption of IL-2, and spontaneously expanded suppressor cell function by mononuclear cells from 15 patients with systemic lupus erythematosus (SLE) and 15 healthy control subjects. These functions were studied in the presence or absence of AS-101, a recently described organotellurium compound with immunoregulatory properties. AS-101 was found to be non-toxic to cells from both patient and control groups; it increased the production of IL-2, elevated the percentage of Tac-positive cells even among cells that had been pre-treated with pronase, and ameliorated the absorption of IL-2. It also enhanced the suppressor cell function in cells from SLE patients. Since these functions are known to be defective in vitro in cells of SLE patients, and since preliminary testing of AS-101 in humans indicates that it is a safe drug, this immunoregulatory compound holds promise for a novel and effective treatment of SLE.

Full text

PDF
319

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abdou N. I., Sagawa A., Pascual E., Hebert J., Sadeghee S. Suppressor T-cell abnormality in idiopathic systemic lupus erythematosus. Clin Immunol Immunopathol. 1976 Sep;6(2):192–199. doi: 10.1016/0090-1229(76)90110-0. [DOI] [PubMed] [Google Scholar]
  2. Alarcon-Segovia D., Alcocer-Varela J., Diaz-Jouanen E. The connective tissue diseases as disorders of immune regulation. Clin Rheum Dis. 1985 Dec;11(3):451–469. [PubMed] [Google Scholar]
  3. Alcocer-Varela J., Alarcón-Segovia D. Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus. J Clin Invest. 1982 Jun;69(6):1388–1392. doi: 10.1172/JCI110579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bresnihan B., Jasin H. E. Suppressor function of peripheral blood mononuclear cells in normal individuals and in patients with systemic lupus erythematosus. J Clin Invest. 1977 Jan;59(1):106–116. doi: 10.1172/JCI108607. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fishbein E., Alcocer-Varela J., Alarcón-Segovia D. Cellular bases of the production of and response to interleukin-2 in man: role of autologous rosette-forming T-cell subsets defined with monoclonal antibodies. Immunology. 1983 Oct;50(2):223–227. [PMC free article] [PubMed] [Google Scholar]
  6. Frajman M., Díaz-Jouanen E., Alcocer-Varela J., Fishbein E., Guevara M., Alarcón-Segovia D. Effect of pregnancy on functions of circulating T cells from patients with systemic lupus erythematosus: correction of T-cell suppression and autologous mixed-lymphocyte responses. Clin Immunol Immunopathol. 1983 Oct;29(1):94–102. doi: 10.1016/0090-1229(83)90010-7. [DOI] [PubMed] [Google Scholar]
  7. Gillis S., Ferm M. M., Ou W., Smith K. A. T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol. 1978 Jun;120(6):2027–2032. [PubMed] [Google Scholar]
  8. Robb R. J., Rusk C. M. High and low affinity receptors for interleukin 2: implications of pronase, phorbol ester, and cell membrane studies upon the basis for differential ligand affinities. J Immunol. 1986 Jul 1;137(1):142–149. [PubMed] [Google Scholar]
  9. Ruiz-Arguelles A., Alarcón-Segovia D., Llorente L., Del Giudice-Knipping J. A. Heterogeneity of the spontaneously expanded and mitogen-induced generation of suppressor cell function of T cells on B cells in systemic lupus erythematosus. Arthritis Rheum. 1980 Sep;23(9):1004–1009. doi: 10.1002/art.1780230907. [DOI] [PubMed] [Google Scholar]
  10. Sredni B., Caspi R. R., Klein A., Kalechman Y., Danziger Y., Ben Ya'akov M., Tamari T., Shalit F., Albeck M. A new immunomodulating compound (AS-101) with potential therapeutic application. Nature. 1987 Nov 12;330(6144):173–176. doi: 10.1038/330173a0. [DOI] [PubMed] [Google Scholar]
  11. Sredni B., Caspi R. R., Lustig S., Klein A., Kalechman Y., Danziger Y., Ben Ya'akov M., Tamari T., Shalit F., Albeck M. The biological activity and immunotherapeutic properties of AS-101, a synthetic organotellurium compound. Nat Immun Cell Growth Regul. 1988;7(3):163–168. [PubMed] [Google Scholar]
  12. Tan E. M., Cohen A. S., Fries J. F., Masi A. T., McShane D. J., Rothfield N. F., Schaller J. G., Talal N., Winchester R. J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271–1277. doi: 10.1002/art.1780251101. [DOI] [PubMed] [Google Scholar]
  13. Teshigawara K., Wang H. M., Kato K., Smith K. A. Interleukin 2 high-affinity receptor expression requires two distinct binding proteins. J Exp Med. 1987 Jan 1;165(1):223–238. doi: 10.1084/jem.165.1.223. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES